To include your compound in the COVID-19 Resource Center, submit it here.

CDER prevails in Avastin hearing

Six members of FDA's Oncologic Drugs Advisory Committee (ODAC) unanimously backed CDER's proposal to withdraw accelerated approval for Genentech Inc.'s Avastin bevacizumab in combination with chemotherapy to treat first-line HER2-negative

Read the full 303 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE